Fractyl Health Meets Six-Month Primary Endpoint in Revita Obesity Trial, Supporting FDA Submission Plans

Fractyl Health reports statistically significant reductions in weight regain following GLP-1 discontinuation, advancing its Revita treatment toward a potential FDA submission in late 2026. Key Investor TakeawaysFractyl Health (NASDAQ:GUTS) met the six-month co-primary endpoint in its 308-participant REMAIN-1 pivotal study, demonstrating a statistically significant reduction in weight regain (p=0.